FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Myelodysplastic Syndrome. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of FHD-286’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for FHD-286 is expected to reach an annual total of $241 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FHD-286 Overview
Foghorn Therapeutics Overview
Foghorn Therapeutics (Foghorn) is a clinical-stage biotechnology company that focuses on the development of a new class of medicines aimed at treating serious diseases by correcting abnormal gene expression. The company’s primary activities include the modulation of the chromatin regulatory system, which orchestrates gene expression in cells, using their proprietary gene traffic control platform. Foghorn Therapeutics products pipeline includes FHD-286 (BRM / BRG1), FHD-609 (BRD9), Selective BRM, and ARID1B. Its potential therapies are used for treatment spectrum of diseases, including various types of cancer. Foghorn is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$34.2 million for the fiscal year ended December 2023 (FY2023), an increase of 77.6% over FY2022. The operating loss of the company was US$107.9 million in FY2023, compared to an operating loss of US$117.1 million in FY2022. The net loss of the company was US$98.4 million in FY2023, compared to a net loss of US$108.9 million in FY2022.
The company reported revenues of US$6.9 million for the second quarter ended June 2024, an increase of 36.4% over the previous quarter.
For a complete picture of FHD-286’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.